Simão VP, Cury CS, Tavares GMZ, Ortega GC, Ribeiro AC, Santos GS, Lana JFSD. Platelet-rich plasma application in diabetic ulcers: A review. World J Dermatol 2022; 10(1): 1-9 [DOI: 10.5314/wjd.v10.i1.1]
Corresponding Author of This Article
Gabriel Silva Santos, BSc, Academic Research, Instructor, Research Scientist, Technician, Biomedical Science, Brazilian Institute of Regenerative Medicine, 1386 Presidente Kennedy Avenue, Indaiatuba 13334-170, São Paulo, Brazil. gabriel1_silva@hotmail.com
Research Domain of This Article
Orthopedics
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Dermatol. Jun 2, 2022; 10(1): 1-9 Published online Jun 2, 2022. doi: 10.5314/wjd.v10.i1.1
Platelet-rich plasma application in diabetic ulcers: A review
Victoria Pereira Simão, Carolina Souza Cury, Gabriel Mota Zamariolli Tavares, Gabriel Calixto Ortega, Arthur Cichetto Ribeiro, Gabriel Silva Santos, José Fábio Santos Duarte Lana
Victoria Pereira Simão, Carolina Souza Cury, Gabriel Mota Zamariolli Tavares, Gabriel Calixto Ortega, Arthur Cichetto Ribeiro, Medical School, Centro Universitário Lusíada, Santos 11045-101, São Paulo, Brazil
Gabriel Silva Santos, Biomedical Science, Brazilian Institute of Regenerative Medicine, Indaiatuba 13334-170, São Paulo, Brazil
José Fábio Santos Duarte Lana, Department ofOrthopedics, Brazilian Institute of Regenerative Medicine, Indaiatuba 13334-170, São Paulo, Brazil
Author contributions: Simão VP wrote the manuscript; Santos GS proposed the research subtopics; Cury CS and Tavares GMZ were responsible for navigating the literature and sharing the relevant studies that were included in this review; Lana JFSD shared significant knowledge regarding the use of PRP in regenerative medicine; Ortega GC formatted the citations and compiled the references; Ribeiro AC revised and formatted the body of the manuscript, verifying spelling, punctuation and grammatical errors.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gabriel Silva Santos, BSc, Academic Research, Instructor, Research Scientist, Technician, Biomedical Science, Brazilian Institute of Regenerative Medicine, 1386 Presidente Kennedy Avenue, Indaiatuba 13334-170, São Paulo, Brazil. gabriel1_silva@hotmail.com
Received: December 15, 2021 Peer-review started: December 15, 2021 First decision: March 16, 2022 Revised: March 29, 2022 Accepted: April 24, 2022 Article in press: April 24, 2022 Published online: June 2, 2022 Processing time: 166 Days and 13.9 Hours
Abstract
There are 422 million diabetic people in the world. 25% of these individuals are diagnosed with diabetic foot ulcer (DFU). 20% of patients with DFU will suffer amputation of the lower limbs. Following amputation procedures, the mortality rate of patients is over 70% in 5 years. Diabetes has no cure and, therefore, treatment aims to prevent and treat its complications. Autologous platelet-rich plasma (PRP) has been shown to be a therapeutic tool for many types of disorders, including the treatment of DFU. This manuscript aims to carry out a review to provide more knowledge about the efficacy and safety of autologous PRP for wound closure in patients with DFU. The majority of studies included in this review state that PRP promotes improvement of DFU lesions by accelerating tissue healing processes. However, many studies have a small sample size and thus require larger sample range in order to improve robustness of data in the literature.
Core Tip: Platelet-rich plasma (PRP) can be produced by the centrifugation of a patient's peripheral blood, separating the mixture into distinct layers containing plasma, platelets, leukocytes and erythrocytes. An elevated concentration of platelets above the basal value enables accelerated growth of bone and soft tissues with minimal side effects. Autologous PRP administration is a relatively new biotechnology undergoing expansion which continues to reveal optimistic results in the stimulation and enhanced healing of various sorts of tissue injuries.
